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A B S T R A C T
Oral squamous cell carcinoma (OSCC) is a common malignancy of the head and neck region. OSCC has a re-
latively low survival rate and the incidence of the disease is increasing in some geographic areas. Staging and
grading of OSCC are established prerequisites for management, as they influence risk stratification and are the
first step toward personalized treatment. The current AJCC/UICC TNM staging (8th edition, 2017) of OSCC has
included significant modifications through the incorporation of depth of invasion in the T stage and extra-
capsular spread/extranodal extension in the N stage. Further modifications for AJCC 8 have been suggested. On
the other hand, the World Health Organization (WHO) classification (4th edition, 2017) still endorses a simple,
differentiation-based histopathologic grading system of OSCC (despite its low prognostic value) and ignores
factors such as tumor growth pattern and dissociation, stromal reactions (desmoplasia, local immune response),
and tumor-stroma ratio. The various controversies and possible developments of the current staging and grading
criteria of OSCC are briefly discussed in this update together with possible applications of artificial intelligence
in the context of screening and risk stratification.
Introduction
Oral cancer is a significant health problem and regarded as the main
cause of death from oral diseases in many countries. Recent global es-
timates have revealed 354,864 new cases and 177,384 deaths in 2018
[1]. Traditional risk factors of oral cancer include tobacco and alcohol
abuse. Conventional oral squamous cell carcinoma (OSCC) is one of the
most common cancers of the head and neck; the incidence of OSCC has
increased in many countries, especially in younger age groups [2,3].
Whether or not young and old patients with OSCC have a different
prognosis remains a controversial issue [4,5]. However, no significant
differences were observed in the tumor stage or grade in recent studies
that compared the characteristics of OSCC in young and old patients
[4,6,7]. The oral tongue is the most common subsite and is associated
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with higher mortality than OSCC in other subsites (e.g. floor of mouth,
gingivae, and retromolar trigone) according to a recent analysis of
Surveillance, Epidemiology, and End Results (SEER) database [8].
Management of OSCC is based on surgical resection with or without
adjuvant treatment (e.g. radiotherapy or chemoradiotherapy). The in-
dication for adjuvant treatment is influenced by features detailed in the
standardized histopathology report of the resection, which include
differentiation, growth pattern, depth of invasion, status of margins,
vascular/neural invasion, bone involvement, nodal status (number of
lymph nodes involved, size of largest metastasis, extracapsular spread
(ECS)/extranodal extension (ENE)), and pTNM staging. Standardized
histopathological reporting has been pioneered by the minimum data
sets issued by the Royal College of Pathologists (United Kingdom) in
2005 [9]; and an international version has been published recently
[10]. Because recent studies are centered on the role of immunotherapy
with the use of immune checkpoint inhibitors, PDL-1 im-
munohistochemical staining of tumor biopsies becomes important in
guiding patient selection for PD-1/PD-L1 inhibitor therapy [11].
TNM staging of OSCC
The TNM system of cancer staging reflects the extent of tumor
growth in the whole body and is based on assessment of the size of the
primary tumor (T), involvement of locoregional lymph nodes (N), and
distant metastases (M). This classification is important for treatment
planning, estimating risk of recurrence, and assessment of overall sur-
vival. However, this classification only considers the anatomic exten-
sion of the disease and not the other prognostic factors, such as co-
morbidity or treatment [12].
The International Union Against Cancer (UICC) published the first
edition of the TNM staging in 1968, whereas the American Joint
Committee on Cancer (AJCC) published its first staging manual in 1977.
Later editions were synchronized and effected updating. In 2017, the
8th edition of the UICC and AJCC (AJCC 8) staging manual was re-
leased [13,14]. It introduced two major changes for OSCC, namely in-
corporation of the tumor depth of invasion (DOI) in the T stage and
incorporation of extracapsular spread (ECS) in the N stage. Several
studies have examined the performance of AJCC 8 in independent co-
horts of OSCC [15–18] and the need for further development is ac-
knowledged.
DOI, also known as reconstructed tumor thickness, is different from
clinical tumor thickness, particularly in exophytic and ulcerated lesions.
DOI was originally envisaged as distance from a theoretical re-
constructed normal mucosal surface line to the deepest extent of growth
[19,20]. Recently, Müller et al. (2019) favored the level of the epithelial
basement membrane zone instead of the normal mucosal surface [10],
although the value of this is debatable. The AJCC 8 manual and UICC
Atlas suggest that DOI can be reliably defined clinically, but DOI seems
difficult to estimate by palpation only. An alternative to overcome these
difficulties would be the use of preoperative imaging (e.g. magnetic
resonance imaging (MRI) or ultrasound (US)) to assess the depth of
invasion and tumor thickness. In a retrospective study, Dirven et al.
found that the T category and the TNM stage prognostic performance of
the AJCC 8 staging of oral cancer is similar regardless of whether DOI or
tumor thickness was used as the T-category modifier [18].
A recent systematic review and a meta-analysis, including in-
dividual participant data of 240 patients, showed a high correlation of
tumor thickness within this subgroup as measured by intraoral US and
histopathology (r = 0.82, P < 0.001), with minor overestimation of
0.5 mm on US [21]. It was concluded that intraoral US is very accurate
in determining tumor thickness in early oral tongue cancer [21]. This
was confirmed in a more recent systematic review including 471 pa-
tients, in which a pooled correlation coefficient of 0.95 was observed
[22]. Regarding preoperative imaging (CT or MRI), Weimar et al. [17]
successfully used the measurements of tumor thickness as a modifier for
T stage in AJCC 8; these results were corroborated by Dirven et al. [18].
Lwin et al. [23] compared radiological tumor thickness (RTT) with
histological tumor thickness (HTT) for OSCC and reported that al-
though RTT shows a somewhat predictable relationship with HTT, this
varies between sub-sites with better results for tongue using axial MRI.
These authors acknowledged the need for evaluating the role of bio-
markers and US. In this context, Brouwer de Koning et al. [24] recently
reported that tumor thickness for preoperative staging of OSCC can be
more accurately measured with US than with MRI.
It has been emphasized that the modifications included in AJCC 8
have caused upstaging of many cases according to recently published
studies [15,18,25]. In a recent analysis of a large cohort, Lee et al. [26]
reported that upstaging has occurred in 12.4% of cases for pT stage, in
13.3% for the pN stage, and in 24.8% for the overall stage. Similarly,
when DOI was incorporated for cT stage of early oral tongue cancer,
upstaging was noted [15]. This would influence treatment planning, as
OSCC cases that were early stage according to AJCC 7 are now upstaged
as advanced lesions according to AJCC 8. In a series of 199 patients
with AJCC 7 cT1-2N0 oral cancer subjected to sentinel node biopsy, a
(pretreatment) clinical upstage (to T3) of 8% was found [27].
The implementation of AJCC 8 has been influenced by the multiple
corrections made to the original printed edition and by the fact that the
histopathological assessment of DOI in some cases is subject to un-
certainty and inter-observer variability. For instance, according to the
first version of AJCC 8, tumors > 4 cm or any tumor with
DOI > 10 mm were considered T3. This statement contrasts with the
latest version of the erratum, which defines T3 as tumors be-
tween > 2 cm and ≤ 4 cm with DOI > 10 mm or tumors > 4 cm with
DOI ≤ 10 mm [28]. Therefore, it was not made clear until the third
version that it is DOI in conjunction with tumor size that determines the
T category. It is imperative to be aware of these corrections as these
changes may affect the interpretation and conclusions of some clinical
studies related to the performance of AJCC 8.
A suggestion has been made to lower the threshold of T stage. As an
example, Almangush et al. suggested lowering the cutoff point (from
5 mm to 2 mm for T1 and from 10 mm to 4 mm for T2) to better
categorize the risk groups of early oral tongue cancer cases [15]. Fur-
ther, recent studies [16,29,30] have proposed considering the number
of positive metastatic nodes to modify the N stage. Determining the
ideal cutoff point of DOI and the number of positive nodes used as
modifiers of T and N stages with adequate risk discrimination still re-
quires further validation studies to examine these recently proposed
modifications.
In an attempt to improve recognition of DOI and reconstructed
thickness, Woolgar and Triantafyllou [19,20,31] used linear segments
and curved lines on histopathological photomicrographs, a practice
later endorsed by Lydiatt et al. [32] and Müller et al. [10]. It is observed
that Lydiatt et al. [32] drew a horizontal line to the closest adjacent
intact mucosa and dropped a “plumb” line perpendicular to it, but it
appears that a study of the figures suffices. Obtaining slices of tissue
perpendicular to the mucosal surface during macroscopical cutting is of
paramount significance in establishing DOI. Such slices are often easier
to obtain in segmental glossectomies, including the curvature of the
lateral border of the tongue. Purported cases where DOI can be un-
derestimated or overestimated include absence of adjacent intact mu-
cosa, absence or only minimal residual tumor after biopsy, extra-
tumoral perineural or vascular invasion, and a positive deep margin
[33]. However, the absence of adjacent mucosa seems unlikely in re-
sections. In cases of a positive deep margin, the pathologist should
measure and report what has been available (resections are
likely > 5.0 mm thick); hence, the tumor would be of an adversely
prognostic thickness and precise measurement would not influence
clinical decisions. More challenging is the case of perineurial invasion.
If “satellites” are present ahead of the main front, the sensible action
would possibly be to measure the DOI of the mass and also to include in
the pathology report the distance of the perineurial invasion from the
main tumor front (Fig. 1) [34]. If the tumor shows a dispersed growth
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pattern and perineurial invasion [10], it would seem sensible to regard
the distance between the mucosal surface and the nerve involved as
DOI.
Histopathological grading of OSCC
Histopathological grading was first introduced by Broders for
squamous cell carcinoma of the lip and was based on the differences in
differentiation between tumors [35]. Later, more complex grading
systems were suggested by Jakobsson et al. [36], Anneroth et al. [37],
and Bryne et al. [38]. These multifactorial systems consider features of
the tumor per se (e.g. differentiation), the tumor host interface (inva-
sion patterns), and host reactions (inflammatory response). They in-
fluenced formulating the concept of favorable/cohesive and dys- and
non-cohesive patterns of invasion in the minimum data sets of the Royal
College of Pathologists (United Kingdom) [19,20], to which a dispersed
pattern was recently added [10]. These systems should be updated by
introducing the feature of myofibroblasts or cancer-associated fibro-
blasts, which often assessed with the use of immunohistochemistry for
alpha smooth muscle actin [39,40].
Curiously, the World Health Organization (WHO) did not endorse
such multifactorial systems and paid little attention to minimum data
sets or standardized histopathological reporting. The current edition of
the Classification of Head and Neck Tumors supports a simple grading
system [41] based on the Broders criteria and merely recognizes well-,
moderately-, and poorly-differentiated variants of conventional OSCCs,
although they acknowledge that “Grading alone does not correlate well
with prognosis” [41]. Many studies indicate minor or no prognostic
value of the WHO grading system [42,43]. The data sets of the Royal
College of Pathologists (United Kingdom) [9] and sets from Müller et al.
[10] would be the sensible alternative.
The dys-/non-cohesive and dispersed invasive patterns defined in
the aforementioned sets also likely include tumor budding. Elseragy
et al. [44] added tumor budding to the WHO differentiation criteria and
showed a better prognostic value than the conventional WHO system in
a series of early oral tongue SCC [44]. Further validation in large co-
horts of OSCC would be desirable.
A different approach was based on tumor budding and the size of
cell nests but was independent of the degree of cell differentiation [45].
Arora et al. assessed the prognostic significance of multiple features,
including T stage, tumor grade, tumor budding, tumor thickness, depth
of invasion, shape of tumor nests, lymphoid response at the tumor-host
interface, and the pattern of invasion, eosinophilic reaction, foreign-
body giant cell reaction, lymphovascular invasion, and perineural in-
vasion [46]. They reported that on univariate and multivariate ana-
lyses, seven of these were independent variables for predicting lymph
node metastasis. In descending order, these were depth of invasion
(P = 0.003), pattern of invasion (P = 0.007), perineural invasion
(P= 0.014), grade (P= 0.028), lymphovascular invasion (P= 0.038),
lymphoid response (P= 0.037), and tumor budding (P= 0.039). It was
observed that the pattern of invasion scores higher than tumor budding,
but the relationship between these features should be clarified.
Whatever that relationship may be, “tumor budding” has become
fashionable as a potential prognostic feature in OSCC [47–49]. Such a
trend reflects an appealing terminology and the endorsement of the
concept of tumor budding also in other cancers [50,51].
Assessing tumor and stromal features to improve risk stratification
Traditional approaches in histopathological grading are centered on
the tumor per se (e.g. differentiation, mitotic activity, DOI) rather than
stroma and host responses. The multifactorial systems suggested by
Jakobsson et al.[36], Anneroth et al. [37], and Bryne et al. [38,52]
attempted to make improvements. Currently, the role of the micro-
environment in tumor progression spearheads cancer research [53].
The significance of myofibroblasts and cancer-associated fibroblasts
was already mentioned above.
Stromal myofibroblasts are innate components of the so-called
desmoplastic reaction (desmoplasia) in OSCC [19,20]. Except for
myofibroblasts, stromal glycosaminoglycans (GAGs) are also involved
in that reaction. Although usually assessed by mucosubstance his-
tochemistry and immunohistocemistry, GAGs can also be studied by
immunohistochemistry and visualized to some degree also in routine
HE sections (Fig. 2) [19,20]. However, little attention has been paid to
the role of GAGs as possible prognosticators in OSCC [54].
Fig. 1. SCC invades nerve fascicles ahead of its main front. Key: e, surface,
epithelial; gl, glands; mu, muscle; N, nerves; T, tumor; to, tonsil. The curved line
indicates the main front. The distance between invaded nerves and main front
(straight line) should be measured (H & E). Modified from Woolgar JA,
Triantafyllou A. A histopathological appraisal of surgical margins in oral and
oropharyngeal cancer resection specimens. Oral Oncol. 41:1034-43, 2005.
Fig. 2. (A) GAGs (asterisk) in the stroma of SCC (T) (H & E). They are easily distinguished from tumor or the host inflammatory reaction (inf). Modified from
(Woolgar and Triantafyllou 2011). (B) Histochemistry for mucosubstances demonstrates the Alcianophilia of GAGs (asterisk); the tumor cell aggregates (T) are
unstained.
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The so-called immunoscore has been used to characterize various
cancers [55,56]. Zhou et al. have recently developed an immune-based
prognostic score that includes seven features (such as CD 3 and CD 8)
that has significant clinical relevance for survival [57]. Such assessment
may be used to identify cases that could benefit from immunotherapy
[58]. Endorsing a different approach, Heikkinen et al. suggested that an
overall assessment of stromal tumor-infiltrating lymphocytes (TILs)
allows risk stratification in early stage oral tongue SCC [59]. This as-
sessment can be easily incorporated in routine histopathology reporting
based on HE-stained sections (Figs. 3 and 4). At the same time, recent
studies have used immunohistochemistry and reported the significance
of different subtypes of lymphocytes and other immune cell compo-
nents (e.g. dendritic cells) in the prediction of overall survival and
disease-free survival [60–64]. Based on the accumulated evidence, re-
cent meta-analyses have identified specific immune biomarkers (e.g.
CD57+ and CD163+) for prognostication of OSCC [65,66].
Finally, the tumor-stroma ratio (TSR) was also examined in early-
stage oral tongue SCC and may be of useful prognostic significance
[67]. Stroma-rich tumors (Fig. 3) are associated with increased recur-
rence and mortality compared with stroma-poor tumors (Fig. 4) [67].
Again, the assessment of TSR is simple and easily performed on HE-
stained slides. A recent meta-analysis indicated the importance of TSR
in many cancers [68].
We would like to re-emphasize that the assessment of stromal
myofibroblasts, GAGs, TILs, and TSR is cost-effective and can be in-
cluded in the histopathology report with minimal effort.
Artificial intelligence to improve staging, grading and treatment
planning
Treatment planning is a multifactorial process and many factors and
parameters with a variable impact should be considered in the decision-
making process for management of OSCC. Recently, artificial in-
telligence and machine-learning tools have been used to analyze factors
that could influence the probability of survival, including TNM stage
and WHO grade [69]. Regarding OSCC, Bur et al. [70] used machine
learning and developed a predictive algorithm that consists of many
prognostic factors (including tumor grade) to predict lymph node me-
tastasis in early-stage tumors. Similarly, Kim et al. [71] used many
clinicopathologic characteristics (including stage and grade) for deep
learning prognostication that may improve prediction of survival after
treatment of OSCC. Furthermore, Alabi et al. [72] used machine
learning to construct an artificial neural network and also developed a
web-based tool to allow for the assessment of several parameters (in-
cluding stage and grade) to estimate the risk of recurrence in early oral
tongue cancer [72].
Insights and perspectives
Possible improvements for TNM staging and WHO grading
[15,16,29,30,44] may assist risk stratification of OSCC. The role of the
anatomical sub-site should be considered and distinction between early-
and advanced-stage OSCCs is important. Prospective studies are ne-
cessary. A recent review observes that due to the heterogeneity of
methodological approaches, it is impossible to perform a satisfactory
meta-analysis for the identification of biomarkers specific for OSCC
[73]. Efforts to overcome these difficulties should be undertaken as the
identification of biomarkers that allow the screening and identification
of individuals who are at risk of developing a primary OSCC or predict
relapse after treatment would be a clear way forward. Artificial in-
telligence has recently shown potential as a promising tool to analyze
patient survival based on many factors, including staging and grading.
Further research on OSCC should consider application of artificial in-
telligence in large multi-institutional studies.
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Fig. 3. SCC with stroma-rich tumor. The stroma includes areas of a fibrous appearance intermingled with lymphocytic infiltrates. The infiltrates are associated with
loose matrix and they are often located around carcinomatous components of non-cohesive, dispersive, or budding (arrows) growth patterns.
Fig. 4. In comparison with Fig. 3, this SCC shows stroma-poor tumor. The
stroma shows widespread lymphocytic infiltration in a largely loose matrix;
fibrous areas are inconspicuous.
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